Creative Biolabs Unveils Complete Innovative Macrophage Solutions

October 27 09:49 2022
Creative Biolabs is determined to provide a wide range of custom macrophage services to advance macrophage therapeutic development and related studies, having established a high-standard macrophage development platform and being equipped with advanced technologies.

New York, USA – October 27, 2022 – Immune system dysfunction underpins a variety of human diseases, so it is urgent to develop novel immunomodulatory therapeutic approaches. With a number of macrophage targeting strategies having been developed in recent years, experimental findings have demonstrated the potency of macrophages in becoming targets for disease control. Seeing the enormous potential of macrophage therapeutic development, Creative Biolabs called for a team of experts who have been working in this field for years to create a comprehensive set of macrophage therapeutic development services and innovative solutions for global customers.

Studies have shown that one of the greatest obstacles to achieving successful immunotherapy regards the existence of the immunosuppressive tumor microenvironment. In fact, immunosuppression in many tumors is caused by the presence of M2-polarized macrophages, which also emphasizes the cruciality of macrophage reprogramming for the development of macrophage therapeutics.

Equipped with cutting-edge macrophage therapeutic development platforms and professional technologies, scientists at Creative Biolabs are dedicated to offering complete solutions for macrophage reprogramming and are willing to address the scientific and technical problems in the process of macrophage reprogramming.

“To better serve our clients’ research and project development, we have improved our technical pipelines for M1 macrophage identification and M2 macrophage identification,” noted a scientist at Creative Biolabs.

Following hundreds of successful collaborations with customers in macrophage identification, Creative Biolabs has accumulated abundant experience in the identification of M1 and M2 macrophages by quantifying macrophage markers. In addition, Creative Biolabs’ scientists have mastered a variety of technologies for the identification of M1 and M2 macrophages of the human or mouse species to meet the unique needs of its clients, including:

* Real-time PCR

* Liquid chromatography-tandem mass spectrometry

* Western blot (WB)

* Immunohistochemistry

* Flow cytometry (FC)

Moreover, the scientific team at Creative Biolabs has invented machine-learning algorithms that can automatically identify M1 and M2 macrophage functional phenotypes based on cell size and morphology.

“We have faith in the quality of our services for macrophage identification and reprogramming because each expert has a wealth of knowledge and expertise in this area,” added the scientist, “and we always put the needs of our customers first.”

To learn more about macrophage therapeutic development services at Creative Biolabs, please visit

About Creative Biolabs

Creative Biolabs, as a reputed leader in the development of macrophage therapeutics, is committed to providing better services to advance science and facilitate customers’ research. The company is also confident in its ability to deliver excellent and comprehensive macrophage therapeutic development services backed by cutting-edge technologies and a team of scientific minds.

Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-830-6441
Country: United States